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DMSO is used as a treatment for interstitial cystitis and this study examined the effects of luminal DMSO treatment on bladder
function and histology. Porcine bladder was incubated without (controls) or with DMSO (50%) applied to the luminal surface and
the release of ATP, acetylcholine, and LDH assessed during incubation and in tissues strips after DMSO incubation. Luminally
applied DMSO caused ATP, Ach, and LDH release from the urothelial surface during treatment, with loss of urothelial layers also
evident histologically. In strips of urothelium/lamina propria fromDMSO pretreated bladders the release of both ATP and Ach was
depressed, while contractile responses to carbachol were enhanced. Detrusor muscle contractile responses to carbachol were not
affected by DMSO pretreatment, but neurogenic responses to electrical field stimulation were enhanced. The presence of an intact
urothelium/lamina propria inhibited detrusor contraction to carbachol by 53% and this inhibition was significantly reduced in
DMSO pretreated tissues. Detection of LDH in the treatment medium suggests that DMSO permeabilised urothelial membranes
causing leakage of cytosolic contents including ATP and Ach rather than enhancing release of these mediators. The increase in
contractile response and high levels of ATP are consistent with initial flare up in IC/PBS symptoms after DMSO treatment.
1. Introduction
Interstitial cystitis or painful bladder syndrome (IC/PBS)
is a chronic inflammatory bladder disease characterised by
bladder or pelvic pain and irritative voiding symptoms in
the absence of infection or other pathology [1]. However
symptoms are variable and often include urinary urgency
and frequency and painful urination [2]. A range of oral and
intravesical therapies are available for IC/PBS; however, reli-
able evidence from well-designed clinical studies is generally
lacking [3, 4].
Dimethyl sulfoxide (DMSO) has been used since the
1960s to treat the symptoms of IC/PBS [5]. Despite limited
clinical trial data, Rimso-50 which is a 50% (v/v) solution
of DMSO is used to relieve pain and reduce the inflamma-
tion and voiding symptoms observed in patients with this
condition [3, 4]. The exact mechanism of action of DMSO
is not fully understood; however, it is reported to cause
mucosal damage and have analgesic, anti-inflammatory, bac-
teriostatic, and muscle relaxant properties [3, 6, 7]. Borzel-
leca et al. reported that 50% DMSO causes desquamation
of the urothelium without altering the lamina propria [8].
Recently, studies have identified that DMSO directly affects
cellular phospholipid membranes, with DMSO molecules
found to occupy positions just below the lipid head groups
acting as a spacer increasing average lateral distance favour-
ing the entrance of water into the cell. Higher concentrations
of DMSO directly increase lateral expansion of the cellular
bilayer and have been known to cause destruction of cellular
lipid bilayers [9, 10]. Patients commencing treatment with
DMSO often experience an initial flare up of symptoms,
which usually subsides after 2 weeks [3].
DMSO is highly permeable and will come into contact
with the urothelium but possibly also the underlying lamina
propria, detrusor smooth muscle, and the nerves innervating
the bladder wall. The urothelium forms a barrier, protecting
underlying nerves and muscle from contents of the urine;
however, the urothelium and lamina propria also play impor-
tant roles in bladder sensation, with the urothelium releasing
a number of mediators including ATP, acetylcholine (Ach),
prostaglandin E2 (PGE2), nitric oxide (NO) [11], and an
unidentified diffusible substance known as urothelial-derived
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inhibitory factor (UDIF) [12]. These mediators are involved
in modulating sensory nerve activity and also detrusor
function. DMSO has been reported to depress nitric oxide
release from efferent nerves [13].
All 5 muscarinic subtypes are expressed in the human
urothelium and stimulation of these receptors in the urothe-
lium releases ATP, NO, and UDIF [14, 15]. Bladder stretch
during filling triggers ATP release from the urothelium and
also subepithelial myofibroblasts, and this ATP is believed to
be the source of primary excitation of the bladder afferents
by acting on the P2X receptors [16–18].The urothelial P2X
2/3
receptors have been implicated in the sensory role involved
with micturition and also nociception in pathological states
[19, 20]. Myelinated A𝛿 afferent fibres are believed to be
involved in the nonpainful micturition reflex, whereas high
threshold unmyelinated C afferent fibres are activated in
painful, pathological conditions.
Intravesical dimethylsulfoxide (DMSO) is used for the
treatment of interstitial cystitis/painful bladder syndrome
(IC/PBS) although patients initially experience a flare up of
symptoms on commencement of treatment. Little is known
regarding the effects of treatment on bladder function or the
cause of the initial worsening of symptoms.As the urothelium
comes into contact with the highest concentrations of DMSO
during intravesical administration, changes in urothelial
functionmay be involved in the drugs therapeutic actions but
also initial worsening of symptoms.The aim of this study was
therefore to investigate possible changes in urothelial/lamina
propria and detrusor function using an in vitro model to
simulate intravesical DMSO treatment.
2. Materials and Methods
2.1. Drugs, Chemicals, and Reagents. Carbachol (carbam-
ylcholine chloride), adenosine triphosphate (ATP), and
dimethyl sulfoxide (DMSO) were obtained from Sigma-
Aldrich (Castle Hill, New South Wales, Australia). Solutions
were prepared in deionised water and further diluted in
Krebs-bicarbonate solution.
2.2. Luminal Treatment of Porcine Bladder with DMSO. Fresh
bladders from Large White-Landrace pigs (6 months old,
80 kg) were obtained from a local abattoir and immediately
immersed in cold Krebs-bicarbonate solution (composition
in mM: NaCl 118, NaHCO
3
24.9, CaCl
2
1.9, MgSO
4
1.15, KCl
4.7, KH
2
PO
4
1.15, and D-glucose 11.7). The bladders were
opened longitudinally and sheets of full thickness anterior
wall from the dome region were set up in a bath where
separated gassed (5% CO
2
/95% O
2
) solutions bathed the
luminal and serosal surfaces (see Figure 1), allowing dimethyl
sulfoxide (DMSO) to be administered to the luminal surface
only, with Krebs-bicarbonate solution bathing the serosal
surface. The tissues were incubated at 37∘C for 15min with
a therapeutic concentration (50% v/v) of DMSO applied to
the luminal surface. Control bladders were incubated for
15min without the addition of DMSO. Incubation media
were collected immediately after the 15-minute incubation
to measure release of ATP, Ach, and lactate dehydrogenase
Gas in
Krebs-bicarbonate
Urothelium 
DMSO (50% v/v)
solution (37∘C)
(5% CO2/
95% O2)
Detrusor
Figure 1: Schematic figure of the incubation chamber. Full thickness
sheets of bladder dome were sandwiched between two separated
bathing solutions, with each containing gassed (5% CO
2
/95% O
2
)
Krebs-bicarbonate (serosal) or DMSO (urothelial) solution at 37∘C.
Tissueswere incubatedwithDMSO (50% v/v) applied to the luminal
side only for 15min before isolation of the various tissues for
pharmacological analysis.
(LDH) from the luminal surfaces during the treatment. After
the incubation (control or DMSO), tissue strips were then
isolated and set up under 1 g resting tension in organ baths
containing Krebs-bicarbonate solution at 37∘C to allow for
the examination of tissue responses. Four sets of tissues were
examined:
(i) full thickness bladder wall with an intact urothelium
and lamina propria;
(ii) denuded detrusor strips with the urothelium and
lamina propria removed;
(iii) strips of urothelium and lamina propria for recording
of tissue contraction;
(iv) strips of urothelium and lamina propria for the mea-
surement of stretch-induced ATP and acetylcholine
release.
2.3. Functional Organ Bath Studies. To assess the effects of
DMSO on tissue responsiveness, contractile response to ATP
(1mM) and cumulative concentration-response curves to the
muscarinic receptor agonist carbachol (1 nM–10 𝜇M) were
obtained on tissues (i), (ii), and (iii). Isometric contractions
of isolated tissue strips were recorded using a Powerlab data
acquisition system (ADInstruments).
To investigate the effects of DMSO on nerve mediated
responses, detrusor strips denuded of urothelium and lamina
propria (tissues (ii)) were set up under 1 g resting tension
in organ baths and electrically field stimulated via silver
electrodes placed either side of the tissue. Tissues were
stimulated at 1, 5, 10, and 20Hz using 5 s trains of pulses
(20 v, 0.5ms pulse-width) delivered every 100 s. Contractile
responses and the release ofmediators for tissues fromDMSO
pretreatment bladders were compared with those of tissues
from control incubated bladders.
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Tissues (iv) were used to examine the effects of DMSO
on basal and stretch-induced release of mediators from the
urothelium/lamina propria. These tissues were washed and
2min later a sample of the bathing medium was collected
and frozen for later assay of mediators (basal release). The
tissues were then stretched, increasing length by 50%, and the
bathing medium again was collected and frozen for assay of
mediators (stimulated release).
2.4. Measurement of ATP, Ach, and LDH. ATP was measured
using a luciferase-luciferin assay kit (Molecular Probes)
according to the manufacturer’s instructions. Luminescence
wasmeasured using aModulusmicroplate reader (Promega).
Acetylcholine was measured using a fluorescence-based
Amplex Red Acetylcholine Assay kit (Molecular Probes)
according to the manufacturer’s protocol. Fluorescence was
measured on a Modulus Microplate reader (Ex. 540/Em.
590 nm). Leakage of LDH into the incubation media was
measured using LDH Cytotoxicity assay (Cayman Chemi-
cals). Absorbance was measured on a Modulus Microplate
reader (490 nm).
2.5. Bladder Histology. Sections of control and DMSO pre-
treated intact bladder dome were fixed (4% neutral buffered
formalin), processed, and embedded in paraffin. Tissues
were sectioned at 6 𝜇m and placed on uncharged slides.
Sections were stained using haematoxylin and eosin to assess
urothelial integrity and examined using an Olympus CX31
microscope (Olympus Australia Pty. Ltd.) equipped with an
Infinity 2 camera and Infinity Capture software. Image J
software was used to measure relative urothelial thickness in
control and DMSO pretreated tissues.
2.6. Data Analysis and Statistical Procedures. Mean (±SEM)
increases in tension induced by carbachol or electrical field
stimulation were calculated. For responses to carbachol,
individual −Log EC50 (pEC50) values were determined from
the concentration-response curves by the use of GraphPad
Prism 5 software (SanDiego, CA) and mean (±SEM) pEC50
values and maximum responses were calculated. Similarly,
for the mediator release study, mean (±SEM) concentrations
were determined before and after stretch and data for DMSO
and control pretreated bladders were compared. Data were
analysed using a paired Student’s 𝑡-test or one-way ANOVA
with Dunnett’s multiple comparisons test, using Graphpad
InStat3 software (SanDiego, CA). Significance levels were
defined as𝑃 < 0.05. 𝑛 values represent the number of separate
pig bladders examined.
3. Results
3.1. Mediator Release during Incubations. At the end of the
pretreatment period the incubation medium was collected
and assayed for Ach (𝑛 = 5) and ATP (𝑛 = 4). Concentrations
of Ach were significantly greater than those of ATP during
both control (1.22 ± 0.05 𝜇M versus 0.010 ± 0.003 𝜇M,
𝑃 < 0.001) and DMSO incubations (21.3 ± 2.94 𝜇M versus
1.12 ± 0.09 𝜇M,𝑃 < 0.001). The presence of DMSO during
the incubation produced a significant increase in the levels
of both mediators (Figures 2(a) and 2(b)), Ach levels rising
17-fold (𝑃 < 0.001), and ATP levels rising by >100-fold
(𝑃 < 0.001). LDH (7mU/mL) was also detected in luminal
incubation medium from DMSO treated bladders, but none
was detected in matched controls.
3.2. Mediator Release from the Urothelium/Lamina Propria
after Incubation. Isolated strips of urothelium/lamina pro-
pria prepared from control incubated bladders released both
ATP (𝑛 = 4) and Ach (𝑛 = 8) under basal and stretch
conditions.There was a significant increase in ATP release in
response to stretch (Figure 2(c)) in control tissues; however,
basal and stretch-induced ATP release from DMSO treated
tissues were not detected. Ach was released from control
urothelium/lamina propria under basal conditions with no
significant increase in response to stretch. Ach release from
DMSO treated tissue was significantly reduced (Figure 2(d)).
3.3. Contractile Responses following Incubation with DMSO.
Luminal pretreatment of bladders with DMSO (50%) did
not significantly affect detrusor, urothelial, or intact tissue
response to KCl or ATP (𝑛 = 5, data not shown). Similarly,
DMSO pretreatment did not affect subsequent responses of
isolated detrusor smooth muscle strips to the muscarinic
receptor agonist carbachol (Figure 3(a), 𝑛 = 4), with both
pEC50 values and maximum responses to carbachol being
similar in muscle strips from DMSO and control pretreated
bladders (Table 1). However responses of urothelium/lamina
propria strips and the responses of intact bladder strips
(detrusor plus urothelium/lamina propria, 𝑛 = 5) to
carbachol were enhanced after pretreatment with DMSO
(Figures 3(b) and 3(c), Table 1).
The presence of the urothelium/lamina propria in the
intact tissues significantly inhibited contractions of bladder
strips (Figure 3, Table 1). This inhibition was significantly
(𝑃 < 0.05) greater in control tissues (53 ± 7.8%) than in
tissues from DMSO pretreated bladders (33 ± 4.1%).
Detrusor responses to electrical field stimulation (EFS)
were frequency dependent and contractions were increased
in tissues from DMSO pretreated bladders. Contractions to
EFS were greater at all stimulation frequencies examined,
with the differences being statistically significant for the
responses at 5Hz, 10Hz, and 20Hz (Figure 3(d), 𝑛 = 5).
In the presence of atropine (1 𝜇M), detrusor contractions to
EFS were depressed by 68± 10% at 20Hz in control tissues
(𝑃 < 0.001, 𝑛 = 5).The inhibition of responses to EFS by this
muscarinic antagonistwas similar at all frequencies examined
and was not altered significantly by DMSO pretreatment
(75± 6.1% inhibition at 20Hz, 𝑛 = 5).
3.4. Bladder Histology. Representative H and E stained
sections of control and DMSO pretreated bladders
(detrusor + urothelium/lamina propria) are shown
(Figure 4). Typical histological features were clearly
identifiable in sections of control incubated bladder, with
the urothelium and lamina propria thrown into folds and
overlying a deeper smooth muscle layer. However in DMSO
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Figure 2: Effect of DMSO (50% v/v) on (a) ATP and (b) Ach release into incubation medium during bladder pretreatment and also on
subsequent basal and stretch-induced release of (c) ATP and (d) Ach from strips of urothelium/lamina propria. Data represents mean± SEM.
( ∗∗∗𝑃 < 0.001, DMSO pretreated versus control incubated bladders. ∧𝑃 < 0.05, control basal versus control stretch. ∗𝑃 < 0.05, DMSO
pretreated versus control incubated tissues).
pretreated tissues, damage to the luminal layers was
evident. Urothelial thickness was significantly reduced
from 31.1± 1.48 𝜇m in control tissues to 11.3± 0.45 𝜇m in
DMSO treated tissues (𝑛 = 15, 𝑃 < 0.001). In addition, the
folding of the urothelium/lamina propria observed in control
bladders was absent from DMSO pretreated bladders.
4. Discussion
Although the exact mechanism by which DMSO relieves
symptoms associated with IC/PBS is unclear, when applied
to the human skin, it penetrates rapidly and produces
pharmacological effects such as anti-inflammation, analgesia,
and bacteriostasis [21]. For IC/PBS, DMSO is administered
intravesically and, due to the highly absorptive nature of
DMSO, it is likely that not only the urothelium but also
the underlying lamina propria, detrusor smooth muscle, and
nerves innervating the bladderwall will be affected byDMSO.
However, it is the urothelial layer that comes into direct
contact with DMSO and is subject to the highest concentra-
tions.
Treatment with DMSO is usually biweekly for 3 months
and this has been found to be effective for approximately 16
to 72 months [22]. Previous studies have reported urothelial
desquamation, mucosal damage, and interference of cellular
phospholipid membranes to be associated with the applica-
tion of DMSO [3, 6–10]. Chemical injury and subsequent loss
of urothelial layers exposed to DMSO over a 3-month period
may explain some of its effectiveness in treating IC/PBS as it
has been reported that the removal of a diseased urothelium
by laser treatment leads to nonrecurrence of pain for 6–12
months [23]. In the present study, loss of urothelial layers
and mucosal folding were also detected following DMSO
treatment. In addition, the detection of LDH in the luminal
treatment effluent suggests that DMSO permeabilised the
urothelial membranes causing leakage of cytosolic contents.
The high levels of ATP and Ach detected in the treatment
effluent may therefore reflect leakage of these mediators
BioMed Research International 5
Table 1: Mean (±SEM) maximal responses (g) and pEC50 values for carbachol on tissue strips prepared from DMSO or control pretreated
bladders.
Carbachol Urothelium/lamina propria Detrusor smooth muscle Intact bladder strips
Control DMSO Control DMSO Control DMSO
Maximum response (g) 4.2 ± 0.28 6.6 ± 0.35∗∗∗ 17.8 ± 1.4 17.1 ± 0.7 8.3 ± 0.63 11.5 ± 0.94∗
pEC50 4.14 ± 0.09 4.4 ± 0.08 4.37 ± 0.12 4.39 ± 0.07 4.35 ± 0.14 4.45 ± 0.52
∗
𝑃 < 0.05 and ∗∗∗𝑃 < 0.001 when comparing control versus DMSO (50% v/v).
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Figure 3: Cumulative carbachol concentration-response curves (𝑛 ≥ 4) for DMSO (50% v/v) preincubated and control preincubated strips
of (a) denuded detrusor, (b) intact tissue, and (c) urothelium/lamina propria. Detrusor strip responses to electrical field stimulation (d) are
also shown (𝑛 = 5). Data represents mean± SEM. ∗∗∗𝑃 < 0.001 compared to responses of control incubated tissues.
from the urothelium due to physical damage rather than
enhanced levels of release.
High levels of ATP and Ach were observed during lumi-
nal treatment with DMSO, and urothelial mediator release
after treatment was also investigated. Following exposure to
DMSO neither subsequent basal release nor stretch-induced
release of ATP could be detected. Ach release was also
significantly reduced following DMSO treatment. This is
likely due to depletion of ATP and Ach stores during DMSO
treatment and loss of urothelial cells from the mucosal
surface. The inhibition of ATP release in response to stretch
from urothelium treated with DMSO is consistent with
6 BioMed Research International
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Figure 4: Hematoxylin and eosin (H and E) staining of control (a) and (c) and DMSO pretreated (b) and (d) bladders. H and E staining at
(a) and (b) 10x and (c) and (d) 40x.
previous reports which have identified a significant decrease
in ATP release from the urothelium treated with DMSO in
response to stretch [24].
Augmented release of urothelial ATP and changes to
urothelial purinergic P2X and P2Y receptor profiles are
common features of patients suffering from IC/PBS [14]. It
is well established that ATP, released in response to stretch,
acts on afferent nerve P2X
2/3
receptors, playing a sensory role
in the micturition cycle and also nociception in pathological
states [20]. Therefore, lower levels of urothelial ATP release
after treatment with DMSO may be beneficial in correcting
the augmented ATP release and the enhanced afferent nerve
activity observed in IC/PBS.
It has been reported that in the porcine and human
bladder the urothelium/lamina propria releases a factor that
inhibits detrusor contraction [12, 25]. This inhibitory effect
of the urothelium was evident in tissues from both control
and DMSO pretreated bladders, but the inhibitory effect
was significantly reduced followingDMSOpretreatment.The
consequences of this change are unknown, but a similar
reduction in inhibitory mechanisms has been observed in
the human neurogenic overactive bladder [26]. Thus the
observed reduction in urothelial inhibition of the detru-
sor may contribute to the bladder overactivity observed
after DMSO treatment. Surprisingly urothelial contractile
responses to carbachol were enhanced following DMSO
pretreatment. It has been suggested that this activity is
responsible for correct folding of the urothelium on bladder
emptying [27] or contractile activity of this layer may drive
detrusor contraction [28] but the clinical relevance of this
urothelial activity is currently unknown.
Detrusor responses to carbachol were not affected by
DMSO pretreatment suggesting that only lower concentra-
tions of DMSO permeate to these deeper tissues. However
detrusor responses to EFSwere altered by pretreatmentwhich
indicates that the parasympathetic nerves in this tissue are
more sensitive to the actions of DMSO than the detrusor
muscle itself. Unexpectedly, responses to EFS were enhanced
by DMSO pretreatment. Since detrusor responses to exoge-
nous carbachol were unchanged, this suggests that DMSO
increases neurotransmitter release to EFS. The enhanced
responses may be the result of DMSO causing damage to
the nerve terminals which may ease when depletion of these
stores has been completed. This is consistent with previous
research which also noted acute reflex firing of pelvic nerve
efferent axons in response to DMSO [13]. Atropine inhibited
responses to EFS similarly in control and DMSO pretreated
tissues, suggesting that the cholinergic contribution to neu-
rotransmission did not change following treatment.
The acute administration of DMSO has been found to
cause irritation [29] and the associated pain is reportedly
caused by mast cell degranulation, in response to chemical
BioMed Research International 7
injury which eases on depletion [30]. The increase in con-
tractile responses and high levels of ATP are consistent with
initial flare up in IC/PBS symptoms after DMSO treatment.
In conclusion, this study demonstrates a physical and
functional disruption of the bladder urothelium/lamina pro-
pria following luminal exposure to DMSO. During treatment
there was a large release of mediators from the urothe-
lium/lamina propria which are known to trigger micturition
and initiate sensations of pain. These sensations would
be greatly enhanced by the increases in muscarinic and
purinergic receptors previously reported for patients with
IC/PBS. The detection of LDH in the treatment medium
suggests that release was due to permeabilisation of the
urothelial membranes rather than stimulated physiological
release. These effects on mediators and also the reduced
inhibitory role of the urothelium/lamina propria on detrusor
contraction followingDMSOpretreatmentmay contribute to
the initial flare up in symptoms experienced by most patients
following intravesical DMSO treatment. Thus antagonists of
sensory nerve purinergic receptors currently in development
may potentially offer relief during this initial period after
DMSO treatment.
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